Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > TME Relevant Pathway > HGF R > MET-C52H9

Cynomolgus HGF R / c-MET Protein, His Tag

  • Synonym
    MET,AUTS9,HGFR,RCCP2,c-Met
  • Source
    Cynomolgus HGF R, His Tag (MET-C52H9) is expressed from human 293 cells (HEK293). It contains AA Glu 25 - Asn 930 (Accession # A0A2K5UM36-1).
    Predicted N-terminus: Glu 25
  • Molecular Characterization
    Online(Glu 25 - Asn 930) A0A2K5UM36-1

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 103.2 kDa. The protein migrates as 80 kDa under reducing (R) condition (SDS-PAGE).

  • Endotoxin
    Less than 1.0 EU per μg by the LAL method.
  • Purity

    >90% as determined by SDS-PAGE.

  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Storage

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
SDS-PAGE
Cynomolgus HGF R, His Tag (Cat. No. MET-C52H9) SDS-PAGE gel

Cynomolgus HGF R, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 90%.

Bioactivity-ELISA
Cynomolgus HGF R, His TagCynomolgus HGF R, His Tag (Cat. No. MET-C52H9) ELISA bioactivity

Immobilized Cynomolgus HGF R, His Tag (Cat. No. MET-C52H9) at 5 μg/mL (100 μL/well) can bind Human HGF, Fc Tag (Cat. No. HGF-H5253) with a linear range of 0.6-20 ng/mL (QC tested).

Cynomolgus HGF R, His TagCynomolgus HGF R, His Tag (Cat. No. MET-C52H9) ELISA bioactivity

Immobilized Human HGF, Fc Tag (Cat. No. HGF-H5253) at 2 μg/mL (100 μL/well) can bind Cynomolgus HGF R, His Tag (Cat. No. MET-C52H9) with a linear range of 0.039-1.25 μg/mL (Routinely tested).

  • Background
    Hepatocyte growth factor receptor (HGFR) is also known as mesenchymal-epithelial transition factor (MET), c-Met, and is a glycosylated receptor tyrosine kinase that plays a central role in epithelial morphogenesis and cancer development. HGFR protein possesses tyrosine-kinase activity. The primary single chain precursor protein is post-translationally cleaved to produce the alpha and beta subunits, which are disulfide linked to form the mature receptor. HGFR is normally expressed by cells of epithelial origin, while expression of HGF is restricted to cells of mesenchymal origin. Upon HGF stimulation, HGFR induces several biological responses that collectively give rise to a program known as invasive growth. Abnormal HGFR activation in cancer correlates with poor prognosis, where aberrantly active HGFR triggers tumor growth, formation of new blood vessels (angiogenesis) that supply the tumor with nutrients, and cancer spread to other organs (metastasis). HGFR is deregulated in many types of human malignancies, including cancers of kidney, liver, stomach, breast, and brain. Normally, only stem cells and progenitor cells express HGFR, However, cancer stem cells are thought to hijack the ability of normal stem cells to express HGFR, and thus become the cause of cancer persistence and spread to other sites in the body. Various mutations in the HGFR gene are associated with papillary renal carcinoma. HGFR mediates a complex program known as invasive growth. Activation of HGFR triggers mitogenesis, and morphogenesis.
  • Clinical and Translational Updates
      
  • Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.

Comments (0)


ETD of in-stock products: 2 business days

Price(USD) : $350.00

Price(USD) : $2310.00

Recommended Products
Monoclonal Anti-His Tag Antibody

Price(USD) : $250.00

Price(USD) : $1580.00

HRP conjugated Anti-His Tag Antibody

Price(USD) : $250.00

Price(USD) : $1680.00

Promotion & Exhibitions



Drug Development Status

  • Number of Launched Drugs:7 Details
  • Number of Drugs in Clinical Trials:44 Details
  • Latest Research Phase:Approved

Datasheet & Documentation

Request for DMF
DMF (Drug Master File)

Contact Us

+1  800-810-0816 (US)
+86 400-682-2521 (AP)

Related Products

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message